In this episode of Derms and Conditions, Dr James Q. Del Rosso welcomes back his longtime friend and pediatric dermatology expert, Dr Lisa Swanson. Together, they explore the rapidly evolving treatment landscape for pediatric atopic dermatitis, with a focus on newly approved non-steroidal topical therapies. 

Dr Swanson shares her insights on tapinarof 1% cream, now FDA-approved for patients as young as two years old, and topical roflumilast 0.15% cream, approved down to age six. The duo discusses how aryl hydrocarbon receptor (AhR) agonism makes tapinarof effective in both atopic dermatitis and psoriasis, likening its action to a “SNOO” that adjusts to soothe inflammation. 

They also dive into data from the ADORING 1 and ADORING 2 phase 3 trials, highlighting tapinarof’s rapid reduction in itch and its positive impact on sleep—critical outcomes for both children and their parents. Dr Swanson offers real-world anecdotes about the sleep-depriving toll of pediatric eczema and how effective therapies can restore rest for the entire family. 

The conversation touches on skin of color considerations, including how atopic dermatitis may present differently and why diverse representation in clinical trials is essential. Dr Swanson underscores the importance of tactile assessments and shares practical pearls for evaluating eczema severity across skin types. 

Finally, they explore safety and tolerability, emphasizing tapinarof’s low risk of systemic absorption, even in young children prone to thumb-sucking or hand-to-mouth behavior. 

Tune in for clinical pearls, new treatment insights, and a few laughs between two dermatology BFFs.